Molecular profiling of tissue samples from patients who received a Kite-manufactured gene-modified cell therapy and have developed a secondary malignancy of T-cell origin

Study type

• Study topic:
  Disease /health condition

  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Feasibility analysis

Non-interventional study

• Non-interventional study design:
  Other
• Non-interventional study design, other:
  Observational study

Study drug and medical condition

• Name of medicine:
  YESCARTA

  TECARTUS
• Study drug International non-proprietary name (INN) or common name:
  AXICABTAGENE CILOLEUCEL

  BREXUCABTAGENE AUTOLEUCEL
• Medical condition to be studied:
  Diffuse large B-cell lymphoma

  Mantle cell lymphoma

  Follicular lymphoma

  Acute lymphocytic leukaemia

  Primary mediastinal large B-cell lymphoma

Population studied

• Age groups:
  • Adult and elderly population (≥18 years)

    • Adults (18 to < 65 years)

      • Adults (18 to < 46 years)
      • Adults (46 to < 65 years)
    • Elderly (≥ 65 years)

      • Adults (65 to < 75 years)
      • Adults (75 to < 85 years)
      • Adults (85 years and over)